nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Sulindac Metabolic Pathway—CYP1B1—esophageal cancer	0.00673	0.0359	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—ADCYAP1—esophageal cancer	0.00628	0.0335	CbGpPWpGaD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—NOS2—esophageal cancer	0.0057	0.0304	CbGpPWpGaD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00567	0.0303	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—GNG7—esophageal cancer	0.0051	0.0272	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00499	0.0266	CbGpPWpGaD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00497	0.0265	CbGpPWpGaD
Anagrelide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00462	0.0247	CbGpPWpGaD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—NOS3—esophageal cancer	0.00458	0.0245	CbGpPWpGaD
Anagrelide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.0042	0.0224	CbGpPWpGaD
Anagrelide—Blood creatinine increased—Cisplatin—esophageal cancer	0.00408	0.00502	CcSEcCtD
Anagrelide—Dehydration—Cisplatin—esophageal cancer	0.00405	0.00499	CcSEcCtD
Anagrelide—Ecchymosis—Capecitabine—esophageal cancer	0.004	0.00492	CcSEcCtD
Anagrelide—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00398	0.0049	CcSEcCtD
Anagrelide—Abnormal vision—Capecitabine—esophageal cancer	0.00386	0.00475	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—esophageal cancer	0.00378	0.0202	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—PDE4D—esophageal cancer	0.0037	0.0198	CbGpPWpGaD
Anagrelide—Pancreatitis—Cisplatin—esophageal cancer	0.00369	0.00454	CcSEcCtD
Anagrelide—Photosensitivity—Capecitabine—esophageal cancer	0.00366	0.0045	CcSEcCtD
Anagrelide—Skin discolouration—Methotrexate—esophageal cancer	0.00365	0.00449	CcSEcCtD
Anagrelide—Abdominal discomfort—Cisplatin—esophageal cancer	0.00361	0.00444	CcSEcCtD
Anagrelide—Pancytopenia—Cisplatin—esophageal cancer	0.00358	0.0044	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—GNG7—esophageal cancer	0.00352	0.0188	CbGpPWpGaD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.0035	0.0187	CbGpPWpGaD
Anagrelide—Dysarthria—Methotrexate—esophageal cancer	0.00348	0.00429	CcSEcCtD
Anagrelide—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00348	0.00429	CcSEcCtD
Anagrelide—Amnesia—Capecitabine—esophageal cancer	0.00342	0.00421	CcSEcCtD
Anagrelide—Atrial fibrillation—Capecitabine—esophageal cancer	0.00339	0.00417	CcSEcCtD
Anagrelide—Renal impairment—Capecitabine—esophageal cancer	0.00338	0.00415	CcSEcCtD
Anagrelide—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00331	0.00407	CcSEcCtD
Anagrelide—Arthritis—Capecitabine—esophageal cancer	0.00331	0.00407	CcSEcCtD
Anagrelide—Renal failure—Cisplatin—esophageal cancer	0.0033	0.00406	CcSEcCtD
Anagrelide—Myocardial infarction—Cisplatin—esophageal cancer	0.00329	0.00405	CcSEcCtD
Anagrelide—Cardiac failure—Capecitabine—esophageal cancer	0.00329	0.00405	CcSEcCtD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00329	0.0176	CbGpPWpGaD
Anagrelide—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00328	0.00403	CcSEcCtD
Anagrelide—Conjunctivitis—Cisplatin—esophageal cancer	0.00326	0.00402	CcSEcCtD
Anagrelide—Melaena—Methotrexate—esophageal cancer	0.00322	0.00396	CcSEcCtD
Anagrelide—Osteoarthritis—Capecitabine—esophageal cancer	0.00321	0.00395	CcSEcCtD
Anagrelide—Diplopia—Capecitabine—esophageal cancer	0.00321	0.00395	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00321	0.00395	CcSEcCtD
Anagrelide—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00318	0.00391	CcSEcCtD
Anagrelide—Migraine—Capecitabine—esophageal cancer	0.00316	0.00389	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—CYP1B1—esophageal cancer	0.00313	0.0167	CbGpPWpGaD
Anagrelide—Blood creatinine increased—Capecitabine—esophageal cancer	0.00301	0.0037	CcSEcCtD
Anagrelide—Dehydration—Capecitabine—esophageal cancer	0.00299	0.00368	CcSEcCtD
Anagrelide—Ecchymosis—Methotrexate—esophageal cancer	0.00298	0.00367	CcSEcCtD
Anagrelide—Urinary tract disorder—Cisplatin—esophageal cancer	0.00298	0.00366	CcSEcCtD
Anagrelide—Liver function test abnormal—Capecitabine—esophageal cancer	0.00297	0.00365	CcSEcCtD
Anagrelide—Connective tissue disorder—Cisplatin—esophageal cancer	0.00296	0.00365	CcSEcCtD
Anagrelide—Urethral disorder—Cisplatin—esophageal cancer	0.00296	0.00364	CcSEcCtD
Anagrelide—Dry skin—Capecitabine—esophageal cancer	0.00294	0.00362	CcSEcCtD
Anagrelide—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00293	0.00361	CcSEcCtD
Anagrelide—Visual impairment—Cisplatin—esophageal cancer	0.00291	0.00358	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—CAPZA1—esophageal cancer	0.00289	0.0155	CbGpPWpGaD
Anagrelide—Gastritis—Capecitabine—esophageal cancer	0.00284	0.0035	CcSEcCtD
Anagrelide—Eye disorder—Cisplatin—esophageal cancer	0.00282	0.00347	CcSEcCtD
Anagrelide—Tinnitus—Cisplatin—esophageal cancer	0.00281	0.00346	CcSEcCtD
Anagrelide—Lymphadenopathy—Methotrexate—esophageal cancer	0.0028	0.00345	CcSEcCtD
Anagrelide—Cardiac disorder—Cisplatin—esophageal cancer	0.0028	0.00344	CcSEcCtD
Anagrelide—Dysphagia—Capecitabine—esophageal cancer	0.00278	0.00342	CcSEcCtD
Anagrelide—Influenza—Capecitabine—esophageal cancer	0.00278	0.00342	CcSEcCtD
Anagrelide—Asthma—Capecitabine—esophageal cancer	0.00278	0.00342	CcSEcCtD
Anagrelide—CYP1A2—Xenobiotics—CYP2A6—esophageal cancer	0.00275	0.0147	CbGpPWpGaD
Anagrelide—Photosensitivity—Methotrexate—esophageal cancer	0.00272	0.00335	CcSEcCtD
Anagrelide—Mediastinal disorder—Cisplatin—esophageal cancer	0.00272	0.00334	CcSEcCtD
Anagrelide—Angina pectoris—Capecitabine—esophageal cancer	0.0027	0.00333	CcSEcCtD
Anagrelide—Arrhythmia—Cisplatin—esophageal cancer	0.00269	0.00331	CcSEcCtD
Anagrelide—Bronchitis—Capecitabine—esophageal cancer	0.00267	0.00329	CcSEcCtD
Anagrelide—Alopecia—Cisplatin—esophageal cancer	0.00266	0.00328	CcSEcCtD
Anagrelide—Abdominal discomfort—Capecitabine—esophageal cancer	0.00266	0.00328	CcSEcCtD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00265	0.0141	CbGpPWpGaD
Anagrelide—Pancytopenia—Capecitabine—esophageal cancer	0.00264	0.00324	CcSEcCtD
Anagrelide—Malnutrition—Cisplatin—esophageal cancer	0.00262	0.00323	CcSEcCtD
Anagrelide—Dysuria—Capecitabine—esophageal cancer	0.0026	0.00319	CcSEcCtD
Anagrelide—Flatulence—Cisplatin—esophageal cancer	0.00259	0.00318	CcSEcCtD
Anagrelide—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00253	0.00312	CcSEcCtD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00253	0.0135	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00253	0.0135	CbGpPWpGaD
Anagrelide—Weight increased—Capecitabine—esophageal cancer	0.00253	0.00311	CcSEcCtD
Anagrelide—Muscle spasms—Cisplatin—esophageal cancer	0.00252	0.0031	CcSEcCtD
Anagrelide—Weight decreased—Capecitabine—esophageal cancer	0.00251	0.00309	CcSEcCtD
Anagrelide—Pneumonia—Capecitabine—esophageal cancer	0.00249	0.00306	CcSEcCtD
Anagrelide—Vision blurred—Cisplatin—esophageal cancer	0.00247	0.00304	CcSEcCtD
Anagrelide—Depression—Capecitabine—esophageal cancer	0.00247	0.00304	CcSEcCtD
Anagrelide—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00244	0.003	CcSEcCtD
Anagrelide—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00244	0.003	CcSEcCtD
Anagrelide—Ill-defined disorder—Cisplatin—esophageal cancer	0.00244	0.003	CcSEcCtD
Anagrelide—Renal failure—Capecitabine—esophageal cancer	0.00243	0.00299	CcSEcCtD
Anagrelide—Myocardial infarction—Capecitabine—esophageal cancer	0.00243	0.00299	CcSEcCtD
Anagrelide—Anaemia—Cisplatin—esophageal cancer	0.00243	0.00298	CcSEcCtD
Anagrelide—CYP1A2—Estrogen metabolism—CYP1B1—esophageal cancer	0.00241	0.0129	CbGpPWpGaD
Anagrelide—Conjunctivitis—Capecitabine—esophageal cancer	0.00241	0.00296	CcSEcCtD
Anagrelide—Urinary tract infection—Capecitabine—esophageal cancer	0.00241	0.00296	CcSEcCtD
Anagrelide—Osteoarthritis—Methotrexate—esophageal cancer	0.00239	0.00294	CcSEcCtD
Anagrelide—Malaise—Cisplatin—esophageal cancer	0.00237	0.00291	CcSEcCtD
Anagrelide—Haematuria—Capecitabine—esophageal cancer	0.00236	0.0029	CcSEcCtD
Anagrelide—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00234	0.00288	CcSEcCtD
Anagrelide—Epistaxis—Capecitabine—esophageal cancer	0.00234	0.00287	CcSEcCtD
Anagrelide—Convulsion—Cisplatin—esophageal cancer	0.00227	0.0028	CcSEcCtD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00225	0.012	CbGpPWpGaD
Anagrelide—Myalgia—Cisplatin—esophageal cancer	0.00223	0.00275	CcSEcCtD
Anagrelide—Haemoglobin—Capecitabine—esophageal cancer	0.00223	0.00275	CcSEcCtD
Anagrelide—Rhinitis—Capecitabine—esophageal cancer	0.00223	0.00274	CcSEcCtD
Anagrelide—Haemorrhage—Capecitabine—esophageal cancer	0.00222	0.00273	CcSEcCtD
Anagrelide—Hepatitis—Capecitabine—esophageal cancer	0.00222	0.00273	CcSEcCtD
Anagrelide—PDE3A—Platelet homeostasis—NOS2—esophageal cancer	0.00222	0.0119	CbGpPWpGaD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00222	0.00273	CcSEcCtD
Anagrelide—Hypoaesthesia—Capecitabine—esophageal cancer	0.00221	0.00272	CcSEcCtD
Anagrelide—Liver function test abnormal—Methotrexate—esophageal cancer	0.00221	0.00272	CcSEcCtD
Anagrelide—Discomfort—Cisplatin—esophageal cancer	0.00221	0.00272	CcSEcCtD
Anagrelide—Pharyngitis—Capecitabine—esophageal cancer	0.00221	0.00271	CcSEcCtD
Anagrelide—Urinary tract disorder—Capecitabine—esophageal cancer	0.00219	0.0027	CcSEcCtD
Anagrelide—Oedema peripheral—Capecitabine—esophageal cancer	0.00219	0.00269	CcSEcCtD
Anagrelide—Connective tissue disorder—Capecitabine—esophageal cancer	0.00218	0.00269	CcSEcCtD
Anagrelide—Urethral disorder—Capecitabine—esophageal cancer	0.00218	0.00268	CcSEcCtD
Anagrelide—Oedema—Cisplatin—esophageal cancer	0.00214	0.00264	CcSEcCtD
Anagrelide—Visual impairment—Capecitabine—esophageal cancer	0.00214	0.00264	CcSEcCtD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00213	0.0114	CbGpPWpGaD
Anagrelide—Infection—Cisplatin—esophageal cancer	0.00213	0.00262	CcSEcCtD
Anagrelide—Nervous system disorder—Cisplatin—esophageal cancer	0.0021	0.00258	CcSEcCtD
Anagrelide—Thrombocytopenia—Cisplatin—esophageal cancer	0.0021	0.00258	CcSEcCtD
Anagrelide—Tachycardia—Cisplatin—esophageal cancer	0.00209	0.00257	CcSEcCtD
Anagrelide—Skin disorder—Cisplatin—esophageal cancer	0.00208	0.00256	CcSEcCtD
Anagrelide—Eye disorder—Capecitabine—esophageal cancer	0.00208	0.00256	CcSEcCtD
Anagrelide—Tinnitus—Capecitabine—esophageal cancer	0.00207	0.00255	CcSEcCtD
Anagrelide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00207	0.00255	CcSEcCtD
Anagrelide—Asthma—Methotrexate—esophageal cancer	0.00207	0.00254	CcSEcCtD
Anagrelide—Cardiac disorder—Capecitabine—esophageal cancer	0.00206	0.00254	CcSEcCtD
Anagrelide—Anorexia—Cisplatin—esophageal cancer	0.00204	0.00251	CcSEcCtD
Anagrelide—Pancreatitis—Methotrexate—esophageal cancer	0.00203	0.00249	CcSEcCtD
Anagrelide—Mediastinal disorder—Capecitabine—esophageal cancer	0.002	0.00246	CcSEcCtD
Anagrelide—Hypotension—Cisplatin—esophageal cancer	0.002	0.00246	CcSEcCtD
Anagrelide—Chills—Capecitabine—esophageal cancer	0.00199	0.00245	CcSEcCtD
Anagrelide—Arrhythmia—Capecitabine—esophageal cancer	0.00199	0.00244	CcSEcCtD
Anagrelide—Abdominal discomfort—Methotrexate—esophageal cancer	0.00198	0.00244	CcSEcCtD
Anagrelide—Alopecia—Capecitabine—esophageal cancer	0.00196	0.00242	CcSEcCtD
Anagrelide—Pancytopenia—Methotrexate—esophageal cancer	0.00196	0.00242	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00195	0.0024	CcSEcCtD
Anagrelide—Malnutrition—Capecitabine—esophageal cancer	0.00193	0.00238	CcSEcCtD
Anagrelide—Dysuria—Methotrexate—esophageal cancer	0.00193	0.00238	CcSEcCtD
Anagrelide—Paraesthesia—Cisplatin—esophageal cancer	0.00192	0.00237	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—ATP1B2—esophageal cancer	0.00192	0.0102	CbGpPWpGaD
Anagrelide—Dyspnoea—Cisplatin—esophageal cancer	0.00191	0.00235	CcSEcCtD
Anagrelide—Flatulence—Capecitabine—esophageal cancer	0.00191	0.00235	CcSEcCtD
Anagrelide—Erectile dysfunction—Methotrexate—esophageal cancer	0.0019	0.00234	CcSEcCtD
Anagrelide—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00189	0.00232	CcSEcCtD
Anagrelide—Back pain—Capecitabine—esophageal cancer	0.00187	0.0023	CcSEcCtD
Anagrelide—Decreased appetite—Cisplatin—esophageal cancer	0.00186	0.00229	CcSEcCtD
Anagrelide—Muscle spasms—Capecitabine—esophageal cancer	0.00186	0.00229	CcSEcCtD
Anagrelide—Pneumonia—Methotrexate—esophageal cancer	0.00185	0.00228	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00185	0.00228	CcSEcCtD
Anagrelide—Depression—Methotrexate—esophageal cancer	0.00184	0.00226	CcSEcCtD
Anagrelide—Pain—Cisplatin—esophageal cancer	0.00183	0.00225	CcSEcCtD
Anagrelide—Vision blurred—Capecitabine—esophageal cancer	0.00182	0.00224	CcSEcCtD
Anagrelide—Renal failure—Methotrexate—esophageal cancer	0.00181	0.00223	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00181	0.00966	CbGpPWpGaD
Anagrelide—Ill-defined disorder—Capecitabine—esophageal cancer	0.0018	0.00221	CcSEcCtD
Anagrelide—Conjunctivitis—Methotrexate—esophageal cancer	0.00179	0.0022	CcSEcCtD
Anagrelide—Anaemia—Capecitabine—esophageal cancer	0.00179	0.0022	CcSEcCtD
Anagrelide—PDE3A—Platelet homeostasis—NOS3—esophageal cancer	0.00179	0.00953	CbGpPWpGaD
Anagrelide—Sweating—Methotrexate—esophageal cancer	0.00177	0.00217	CcSEcCtD
Anagrelide—Feeling abnormal—Cisplatin—esophageal cancer	0.00177	0.00217	CcSEcCtD
Anagrelide—Haematuria—Methotrexate—esophageal cancer	0.00176	0.00216	CcSEcCtD
Anagrelide—Malaise—Capecitabine—esophageal cancer	0.00174	0.00215	CcSEcCtD
Anagrelide—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00174	0.00214	CcSEcCtD
Anagrelide—Epistaxis—Methotrexate—esophageal cancer	0.00174	0.00214	CcSEcCtD
Anagrelide—Syncope—Capecitabine—esophageal cancer	0.00174	0.00213	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—DOCK2—esophageal cancer	0.00173	0.00926	CbGpPWpGaD
Anagrelide—Palpitations—Capecitabine—esophageal cancer	0.00171	0.0021	CcSEcCtD
Anagrelide—Loss of consciousness—Capecitabine—esophageal cancer	0.0017	0.00209	CcSEcCtD
Anagrelide—Body temperature increased—Cisplatin—esophageal cancer	0.00169	0.00208	CcSEcCtD
Anagrelide—Cough—Capecitabine—esophageal cancer	0.00169	0.00208	CcSEcCtD
Anagrelide—Hypertension—Capecitabine—esophageal cancer	0.00167	0.00206	CcSEcCtD
Anagrelide—Haemoglobin—Methotrexate—esophageal cancer	0.00166	0.00205	CcSEcCtD
Anagrelide—Haemorrhage—Methotrexate—esophageal cancer	0.00165	0.00204	CcSEcCtD
Anagrelide—Hepatitis—Methotrexate—esophageal cancer	0.00165	0.00204	CcSEcCtD
Anagrelide—CYP1A2—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00165	0.0088	CbGpPWpGaD
Anagrelide—Chest pain—Capecitabine—esophageal cancer	0.00165	0.00203	CcSEcCtD
Anagrelide—Myalgia—Capecitabine—esophageal cancer	0.00165	0.00203	CcSEcCtD
Anagrelide—Arthralgia—Capecitabine—esophageal cancer	0.00165	0.00203	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.00164	0.00878	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.00164	0.00878	CbGpPWpGaD
Anagrelide—Pharyngitis—Methotrexate—esophageal cancer	0.00164	0.00202	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00164	0.00201	CcSEcCtD
Anagrelide—Urinary tract disorder—Methotrexate—esophageal cancer	0.00163	0.00201	CcSEcCtD
Anagrelide—Discomfort—Capecitabine—esophageal cancer	0.00163	0.002	CcSEcCtD
Anagrelide—Urethral disorder—Methotrexate—esophageal cancer	0.00162	0.002	CcSEcCtD
Anagrelide—Dry mouth—Capecitabine—esophageal cancer	0.00161	0.00198	CcSEcCtD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.0016	0.00857	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.0016	0.00852	CbGpPWpGaD
Anagrelide—Visual impairment—Methotrexate—esophageal cancer	0.00159	0.00196	CcSEcCtD
Anagrelide—Confusional state—Capecitabine—esophageal cancer	0.00159	0.00196	CcSEcCtD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00158	0.00846	CbGpPWpGaD
Anagrelide—Oedema—Capecitabine—esophageal cancer	0.00158	0.00194	CcSEcCtD
Anagrelide—Infection—Capecitabine—esophageal cancer	0.00157	0.00193	CcSEcCtD
Anagrelide—Shock—Capecitabine—esophageal cancer	0.00155	0.00191	CcSEcCtD
Anagrelide—Nervous system disorder—Capecitabine—esophageal cancer	0.00155	0.00191	CcSEcCtD
Anagrelide—Eye disorder—Methotrexate—esophageal cancer	0.00155	0.0019	CcSEcCtD
Anagrelide—Thrombocytopenia—Capecitabine—esophageal cancer	0.00155	0.0019	CcSEcCtD
Anagrelide—Tinnitus—Methotrexate—esophageal cancer	0.00154	0.0019	CcSEcCtD
Anagrelide—Tachycardia—Capecitabine—esophageal cancer	0.00154	0.0019	CcSEcCtD
Anagrelide—Asthenia—Cisplatin—esophageal cancer	0.00154	0.00189	CcSEcCtD
Anagrelide—Cardiac disorder—Methotrexate—esophageal cancer	0.00154	0.00189	CcSEcCtD
Anagrelide—Skin disorder—Capecitabine—esophageal cancer	0.00153	0.00189	CcSEcCtD
Anagrelide—Hyperhidrosis—Capecitabine—esophageal cancer	0.00153	0.00188	CcSEcCtD
Anagrelide—Anorexia—Capecitabine—esophageal cancer	0.00151	0.00185	CcSEcCtD
Anagrelide—CYP1A2—Tryptophan metabolism—ALDH2—esophageal cancer	0.0015	0.00803	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PFN1—esophageal cancer	0.0015	0.00799	CbGpPWpGaD
Anagrelide—Mediastinal disorder—Methotrexate—esophageal cancer	0.00149	0.00183	CcSEcCtD
Anagrelide—Chills—Methotrexate—esophageal cancer	0.00148	0.00183	CcSEcCtD
Anagrelide—Hypotension—Capecitabine—esophageal cancer	0.00148	0.00182	CcSEcCtD
Anagrelide—Diarrhoea—Cisplatin—esophageal cancer	0.00147	0.0018	CcSEcCtD
Anagrelide—Alopecia—Methotrexate—esophageal cancer	0.00146	0.0018	CcSEcCtD
Anagrelide—Malnutrition—Methotrexate—esophageal cancer	0.00144	0.00177	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00144	0.00177	CcSEcCtD
Anagrelide—Insomnia—Capecitabine—esophageal cancer	0.00143	0.00176	CcSEcCtD
Anagrelide—Paraesthesia—Capecitabine—esophageal cancer	0.00142	0.00174	CcSEcCtD
Anagrelide—Dyspnoea—Capecitabine—esophageal cancer	0.00141	0.00173	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.0014	0.00747	CbGpPWpGaD
Anagrelide—Back pain—Methotrexate—esophageal cancer	0.00139	0.00171	CcSEcCtD
Anagrelide—Dyspepsia—Capecitabine—esophageal cancer	0.00139	0.00171	CcSEcCtD
Anagrelide—Decreased appetite—Capecitabine—esophageal cancer	0.00137	0.00169	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00136	0.00168	CcSEcCtD
Anagrelide—Vomiting—Cisplatin—esophageal cancer	0.00136	0.00168	CcSEcCtD
Anagrelide—Fatigue—Capecitabine—esophageal cancer	0.00136	0.00168	CcSEcCtD
Anagrelide—Vision blurred—Methotrexate—esophageal cancer	0.00136	0.00167	CcSEcCtD
Anagrelide—Rash—Cisplatin—esophageal cancer	0.00135	0.00166	CcSEcCtD
Anagrelide—Pain—Capecitabine—esophageal cancer	0.00135	0.00166	CcSEcCtD
Anagrelide—Constipation—Capecitabine—esophageal cancer	0.00135	0.00166	CcSEcCtD
Anagrelide—Dermatitis—Cisplatin—esophageal cancer	0.00135	0.00166	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—esophageal cancer	0.00134	0.00164	CcSEcCtD
Anagrelide—Anaemia—Methotrexate—esophageal cancer	0.00133	0.00164	CcSEcCtD
Anagrelide—Feeling abnormal—Capecitabine—esophageal cancer	0.0013	0.0016	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.0013	0.00695	CbGpPWpGaD
Anagrelide—Malaise—Methotrexate—esophageal cancer	0.0013	0.0016	CcSEcCtD
Anagrelide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00129	0.00159	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00129	0.00688	CbGpPWpGaD
Anagrelide—Nausea—Cisplatin—esophageal cancer	0.00127	0.00157	CcSEcCtD
Anagrelide—Cough—Methotrexate—esophageal cancer	0.00126	0.00155	CcSEcCtD
Anagrelide—Urticaria—Capecitabine—esophageal cancer	0.00125	0.00154	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00125	0.0067	CbGpPWpGaD
Anagrelide—Body temperature increased—Capecitabine—esophageal cancer	0.00125	0.00154	CcSEcCtD
Anagrelide—Abdominal pain—Capecitabine—esophageal cancer	0.00125	0.00154	CcSEcCtD
Anagrelide—Convulsion—Methotrexate—esophageal cancer	0.00125	0.00154	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—esophageal cancer	0.00123	0.00151	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—esophageal cancer	0.00123	0.00151	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—esophageal cancer	0.00123	0.00151	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00122	0.0015	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—CFL1—esophageal cancer	0.00121	0.00647	CbGpPWpGaD
Anagrelide—Discomfort—Methotrexate—esophageal cancer	0.00121	0.00149	CcSEcCtD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0012	0.00638	CbGpPWpGaD
Anagrelide—Confusional state—Methotrexate—esophageal cancer	0.00119	0.00146	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00117	0.00625	CbGpPWpGaD
Anagrelide—Infection—Methotrexate—esophageal cancer	0.00117	0.00144	CcSEcCtD
Anagrelide—Nervous system disorder—Methotrexate—esophageal cancer	0.00115	0.00142	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—esophageal cancer	0.00115	0.00142	CcSEcCtD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00114	0.00611	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—GNG7—esophageal cancer	0.00114	0.0061	CbGpPWpGaD
Anagrelide—Skin disorder—Methotrexate—esophageal cancer	0.00114	0.0014	CcSEcCtD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00114	0.00609	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.00114	0.00609	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.00114	0.00609	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Methotrexate—esophageal cancer	0.00114	0.0014	CcSEcCtD
Anagrelide—Asthenia—Capecitabine—esophageal cancer	0.00113	0.00139	CcSEcCtD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00113	0.00603	CbGpPWpGaD
Anagrelide—Anorexia—Methotrexate—esophageal cancer	0.00112	0.00138	CcSEcCtD
Anagrelide—Pruritus—Capecitabine—esophageal cancer	0.00112	0.00137	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—esophageal cancer	0.0011	0.00135	CcSEcCtD
Anagrelide—CYP1A2—Phase II conjugation—GSTO1—esophageal cancer	0.0011	0.00586	CbGpPWpGaD
Anagrelide—Diarrhoea—Capecitabine—esophageal cancer	0.00108	0.00133	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GDI2—esophageal cancer	0.00107	0.00573	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00107	0.00572	CbGpPWpGaD
Anagrelide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00107	0.00132	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00107	0.00569	CbGpPWpGaD
Anagrelide—Insomnia—Methotrexate—esophageal cancer	0.00106	0.00131	CcSEcCtD
Anagrelide—Paraesthesia—Methotrexate—esophageal cancer	0.00106	0.0013	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—esophageal cancer	0.00105	0.00129	CcSEcCtD
Anagrelide—Somnolence—Methotrexate—esophageal cancer	0.00104	0.00129	CcSEcCtD
Anagrelide—Dizziness—Capecitabine—esophageal cancer	0.00104	0.00128	CcSEcCtD
Anagrelide—Dyspepsia—Methotrexate—esophageal cancer	0.00103	0.00127	CcSEcCtD
Anagrelide—Decreased appetite—Methotrexate—esophageal cancer	0.00102	0.00126	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00101	0.00125	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—esophageal cancer	0.00101	0.00125	CcSEcCtD
Anagrelide—Pain—Methotrexate—esophageal cancer	0.00101	0.00124	CcSEcCtD
Anagrelide—Vomiting—Capecitabine—esophageal cancer	0.001	0.00124	CcSEcCtD
Anagrelide—Rash—Capecitabine—esophageal cancer	0.000996	0.00123	CcSEcCtD
Anagrelide—Dermatitis—Capecitabine—esophageal cancer	0.000995	0.00122	CcSEcCtD
Anagrelide—Headache—Capecitabine—esophageal cancer	0.000989	0.00122	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000986	0.00526	CbGpPWpGaD
Anagrelide—Feeling abnormal—Methotrexate—esophageal cancer	0.000969	0.00119	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000961	0.00118	CcSEcCtD
Anagrelide—Nausea—Capecitabine—esophageal cancer	0.000938	0.00115	CcSEcCtD
Anagrelide—Urticaria—Methotrexate—esophageal cancer	0.000934	0.00115	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—HSPA5—esophageal cancer	0.000932	0.00497	CbGpPWpGaD
Anagrelide—Abdominal pain—Methotrexate—esophageal cancer	0.000929	0.00114	CcSEcCtD
Anagrelide—Body temperature increased—Methotrexate—esophageal cancer	0.000929	0.00114	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000927	0.00495	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000922	0.00492	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00091	0.00486	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.000888	0.00474	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000879	0.00469	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000867	0.00463	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000855	0.00457	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.000852	0.00455	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000848	0.00453	CbGpPWpGaD
Anagrelide—Asthenia—Methotrexate—esophageal cancer	0.000843	0.00104	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—esophageal cancer	0.000832	0.00102	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—AKAP13—esophageal cancer	0.00083	0.00443	CbGpPWpGaD
Anagrelide—Diarrhoea—Methotrexate—esophageal cancer	0.000804	0.00099	CcSEcCtD
Anagrelide—Dizziness—Methotrexate—esophageal cancer	0.000777	0.000956	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—KMT2D—esophageal cancer	0.000775	0.00414	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000759	0.00405	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKAP13—esophageal cancer	0.000754	0.00403	CbGpPWpGaD
Anagrelide—Vomiting—Methotrexate—esophageal cancer	0.000747	0.00092	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000747	0.00399	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000743	0.00397	CbGpPWpGaD
Anagrelide—Rash—Methotrexate—esophageal cancer	0.000741	0.000912	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—esophageal cancer	0.00074	0.000911	CcSEcCtD
Anagrelide—Headache—Methotrexate—esophageal cancer	0.000736	0.000906	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—GNG7—esophageal cancer	0.000722	0.00386	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000703	0.00375	CbGpPWpGaD
Anagrelide—Nausea—Methotrexate—esophageal cancer	0.000698	0.000859	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000691	0.00369	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000691	0.00369	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ABL1—esophageal cancer	0.00069	0.00368	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PDE4D—esophageal cancer	0.00069	0.00368	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000682	0.00364	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GNG7—esophageal cancer	0.000656	0.0035	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000642	0.00343	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000636	0.0034	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000634	0.00338	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—WWOX—esophageal cancer	0.000632	0.00338	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000625	0.00334	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FKBP1A—esophageal cancer	0.000601	0.00321	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000592	0.00316	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—WIF1—esophageal cancer	0.000588	0.00314	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL2—esophageal cancer	0.000578	0.00309	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—SST—esophageal cancer	0.000575	0.00307	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GHRL—esophageal cancer	0.000561	0.00299	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000542	0.0029	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ANXA1—esophageal cancer	0.000537	0.00287	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000524	0.0028	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—SST—esophageal cancer	0.000523	0.00279	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000514	0.00274	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GHRL—esophageal cancer	0.000509	0.00272	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PFN1—esophageal cancer	0.000507	0.00271	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.000498	0.00266	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS2—esophageal cancer	0.000497	0.00266	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000492	0.00263	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000481	0.00257	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000467	0.00249	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ELMO1—esophageal cancer	0.000456	0.00243	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000449	0.0024	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CREBBP—esophageal cancer	0.000447	0.00239	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKAP13—esophageal cancer	0.000445	0.00238	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000427	0.00228	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000427	0.00228	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000411	0.00219	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDE4D—esophageal cancer	0.000407	0.00218	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS3—esophageal cancer	0.0004	0.00214	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000397	0.00212	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000391	0.00209	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNG7—esophageal cancer	0.000387	0.00207	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000383	0.00204	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000373	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000372	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000368	0.00197	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000364	0.00194	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000364	0.00194	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—XIAP—esophageal cancer	0.000363	0.00194	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CTNNA1—esophageal cancer	0.000343	0.00183	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL2—esophageal cancer	0.000341	0.00182	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSME2—esophageal cancer	0.000319	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSME1—esophageal cancer	0.000319	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ANXA1—esophageal cancer	0.000317	0.00169	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SST—esophageal cancer	0.000309	0.00165	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—EP300—esophageal cancer	0.000304	0.00162	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH3—esophageal cancer	0.000301	0.00161	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GHRL—esophageal cancer	0.000301	0.00161	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FBXW7—esophageal cancer	0.000296	0.00158	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH2—esophageal cancer	0.00027	0.00144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000259	0.00138	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFBR2—esophageal cancer	0.000239	0.00128	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SMAD4—esophageal cancer	0.000227	0.00121	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000226	0.0012	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—esophageal cancer	0.000225	0.0012	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—esophageal cancer	0.000218	0.00116	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000201	0.00107	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000201	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—esophageal cancer	0.000185	0.00099	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000179	0.000957	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—esophageal cancer	0.000177	0.000947	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA1—esophageal cancer	0.000171	0.00091	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000171	0.00091	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH1—esophageal cancer	0.000167	0.000892	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA2—esophageal cancer	0.000156	0.000833	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000152	0.000814	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CREBBP—esophageal cancer	0.000151	0.000809	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—esophageal cancer	0.000149	0.000795	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000145	0.000774	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000145	0.000774	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000143	0.000765	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000142	0.000759	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—esophageal cancer	0.000136	0.000724	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—esophageal cancer	0.000129	0.00069	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADH1B—esophageal cancer	0.000127	0.000679	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB2—esophageal cancer	0.000127	0.000677	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TYMP—esophageal cancer	0.000121	0.000649	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP26A1—esophageal cancer	0.000118	0.000631	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX15—esophageal cancer	0.000115	0.000615	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—esophageal cancer	0.000112	0.000598	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTO1—esophageal cancer	0.00011	0.000587	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TPI1—esophageal cancer	0.00011	0.000587	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1A—esophageal cancer	0.000108	0.000579	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDOB—esophageal cancer	0.000105	0.000562	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EP300—esophageal cancer	0.000103	0.000551	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GAPDH—esophageal cancer	0.000101	0.000541	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CRABP1—esophageal cancer	0.0001	0.000537	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNG7—esophageal cancer	9.56e-05	0.00051	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—esophageal cancer	8.99e-05	0.00048	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH2—esophageal cancer	8.96e-05	0.000478	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—esophageal cancer	8.79e-05	0.000469	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—esophageal cancer	8.52e-05	0.000455	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2A6—esophageal cancer	8.42e-05	0.00045	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.39e-05	0.000448	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ENO1—esophageal cancer	7.98e-05	0.000426	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS1—esophageal cancer	7.98e-05	0.000426	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSME2—esophageal cancer	7.87e-05	0.00042	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSME1—esophageal cancer	7.87e-05	0.00042	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—esophageal cancer	7.63e-05	0.000407	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—esophageal cancer	7.38e-05	0.000394	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.87e-05	0.000367	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.79e-05	0.000362	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP19A1—esophageal cancer	6.38e-05	0.000341	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.82e-05	0.000311	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.71e-05	0.000305	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.59e-05	0.000298	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.23e-05	0.000226	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.74e-05	0.000199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—esophageal cancer	3.34e-05	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.06e-05	0.000163	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EP300—esophageal cancer	2.54e-05	0.000136	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.88e-05	0.0001	CbGpPWpGaD
